Table 1 Patient and sample... | American Society of Hematology

Table 1

Patient and sample characteristics

	Data
Median age at diagnosis, y (range)	60.5 (39-77)
Median age at study entry, y (range)	66 (41-85)
No. men/no. women	54/16
Median time from diagnosis to study entry, mo (range)	62 (9-300)
Rai stage at time of analysis, no. patients
0	9
1	11
2	32
3	3
4	15
Previous therapies, no. patients*
Chlorambucil	17
Chlorambucil/prednisone	18
Fludarabine	14
Other†	11
Median tumor cell content in sample, %† (range)	83 (30-99)

	Data
Median age at diagnosis, y (range)	60.5 (39-77)
Median age at study entry, y (range)	66 (41-85)
No. men/no. women	54/16
Median time from diagnosis to study entry, mo (range)	62 (9-300)
Rai stage at time of analysis, no. patients
0	9
1	11
2	32
3	3
4	15
Previous therapies, no. patients*
Chlorambucil	17
Chlorambucil/prednisone	18
Fludarabine	14
Other†	11
Median tumor cell content in sample, %† (range)	83 (30-99)

Fourteen patients have received more than one regimen.

Assessed by flow cytometry.

Other therapies included alemtuzumab, rituximab, bendamustine, and cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP).